Skip to main content
Clinical and Translational Medicine
Fig. 2 | Clinical and Translational Medicine

Fig. 2

From: Rethinking the combination treatment of fulvestrant and anastrozole for metastatic breast cancer: an integrated reanalysis of aromatase–estrogen receptor axis

Fig. 2

Immunological analyses of CYP19A1–ESR axis in breast cancer. a–c Spearman correlations between CYP19A1, ESR1, ESR2 and multiple TILs across human cancers. For each cancer type, the relative abundance of TILs were inferred by using GSVA based on gene expression profile (TCGA). The readouts of BRCA were highlighted in black frames. d–g Spearman correlations between CYP19A1 and representative immunostimulators (including IL6, TNFRSF8, C10orf54 and CD48) in BRCA (TCGA). h–k Spearman correlations between ESR1 and representative immunostimulators (including IL2RA, TNFRSF8, ULBP1 and CD40) in BRCA (TCGA). l–o Spearman correlations between ESR2 and representative immunostimulators (including TNFRSF13C, TNFRSF17, CD27 and TNFRSF13B) in BRCA (TCGA). The detailed rho and p-value were individually shown as indicated in each panel, and p-value < 0.05 was considered statistically significant

Back to article page